Leadership

The members of Omeros’ leadership team and board of directors bring a wealth of relevant knowledge and expertise, pragmatic judgment, vision and proven track records of success to all aspects of our scientific and corporate strategies.

Leadership Team

Gregory A. Demopulos, MD

Chairman and Chief Executive Officer

Gregory A. Demopulos, MD, founded our company and has served as our president, chief executive officer, and chairman of the board of directors since June 1994. Prior to founding Omeros, Dr Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training in hand and microvascular surgery at Duke University. Dr Demopulos currently serves on the board of trustees of the Smead Funds Trust, an open-end mutual fund company registered under the Investment Company Act of 1940. Dr Demopulos received his MD from the Stanford University School of Medicine and his BS from Stanford University.

Christopher S. Bral, PhD

Vice President
Nonclinical Development

Christopher S. Bral, PhD, joined Omeros as our vice president, nonclinical development in October 2015. From April 2014 to October 2015, Dr Bral was the executive director, toxicology at Arrowhead Research Corporation. From June 2008 to April 2014, Dr Bral served as director, drug safety evaluation at Vertex Pharmaceuticals. Prior to Vertex, Dr Bral held various preclinical drug safety positions of increasing responsibility at Schering-Plough Research Institute including associate director, drug safety evaluation. Dr Bral received his PhD in Biochemistry and Biophysics from Texas A&M University and his BS in Chemistry from John Carroll University, and has been board-certified in toxicology through the American Board of Toxicology since 2000.

Timothy M. Duffy

Vice President
Business Development

Timothy M. Duffy has served as our vice president, business development since March 2010. From November 2008 to March 2010, Mr Duffy served as the managing director of Pacific Crest Ventures, a life science consulting firm that he founded. From June 2004 through September 2008, Mr Duffy served at MDRNA, Inc. (formerly Nastech Pharmaceutical Company, Inc.), a biotechnology company. At MDRNA, he held roles of increasing responsibility in marketing and business development, most recently as the chief business officer. Prior to MDRNA, Mr Duffy served as vice president, business development at Prometheus Laboratories, Inc., a specialty pharmaceutical company, and as a customer marketing manager at The Procter & Gamble Company. Mr Duffy received his BS from Loras College.

Timi Edeki, MD, PhD

Vice President
Clinical Development

Timi Edeki, MD, PhD, joined Omeros as our vice president, clinical development in May 2017. Dr Edeki is a pharmaceutical physician-scientist with experience in developing drugs in multiple therapeutic areas, including nephrology, hematology, cardio-metabolic, immunology, antimicrobials, neuroscience, gastroenterology, oncology, and sepsis. From 2006 through 2016, he served as principal physician for AstraZeneca and, during most of that period, also served as senior director of research and development. From 2003 to 2006, he was associate director at Abbott Laboratories. Dr Edeki is a fellow of the American College of Clinical Pharmacology and currently serves on the editorial board of Clinical Pharmacology and Therapeutics. He currently holds academic appointments as adjunct Professor of Pharmacology, Physiology, and Internal Medicine at Drexel University and previously as Clinical Professor of Medicine at the Chicago Medical School. Dr Edeki received his medical and PhD degrees from the University Lagos and University of London, respectively, and fellowship training at Vanderbilt University. He is a diplomate of both the American Board of Internal Medicine and Clinical Pharmacology.

George A. Gaitanaris, MD, PhD

Chief Scientific Officer

George A. Gaitanaris, MD, PhD, joined Omeros as our vice president, science in August 2006 and has served as our chief scientific officer since January 2012. From August 2003 to our acquisition of nura, inc. in August 2006, Dr Gaitanaris served as the chief scientific officer of nura, a company that he co-founded and that developed treatments for central nervous system disorders. From 2000 to 2003, he served as president and chief scientific officer of Primal, Inc., a biotechnology company that was acquired by nura in 2003. Prior to co-founding Primal, he served as staff scientist at the National Cancer Institute. Dr Gaitanaris received his PhD in cellular, molecular, and biophysical studies, and his MPh and MA from Columbia University, and his MD from the Aristotelian University of Greece.

Michael A. Jacobsen

Chief Accounting Officer

Michael A. Jacobsen joined Omeros in August 2013 as our vice president, finance and has served as our chief accounting officer and treasurer since October 2013. Prior to joining Omeros, Mr Jacobsen served as vice president of finance of Sarepta Therapeutics, Inc., from September 2011 to May 2013 and as its chief accounting officer from September 2011 to December 2012. From April 2007 to August 2011, Mr Jacobsen was vice president and chief accounting officer at ZymoGenetics, Inc. Prior to his service with ZymoGenetics, Mr Jacobsen held various roles at ICOS Corporation, including senior director of finance and corporate controller. From April 1995 to October 2001, Mr Jacobsen held vice president of finance or chief financial officer roles at three companies in the software, computer hardware, and internet retailing industries, two of which were publicly traded. Mr Jacobsen is a certified public accountant and received his bachelor’s degree in accounting from Idaho State University.

Marcia S. Kelbon, JD, MS

General Counsel and Secretary

Marcia S. Kelbon, JD, MS, joined Omeros as our vice president, patent and general counsel in October 2001 and has served as our secretary since September 2007. Prior to joining Omeros, Ms Kelbon was a partner with the firm Christensen O'Connor Johnson & Kindness, PLLC, where she specialized in US and international intellectual property procurement, management, licensing, and enforcement issues. Ms Kelbon received her JD and her MS in chemical engineering from the University of Washington and her BS from The Pennsylvania State University.

Daniel G. Kirby

Vice President
Head of Commercial

Daniel Kirby joined Omeros in November 2018 as vice president, head of commercial. Prior to Omeros, Mr Kirby was the US CAR T-cell commercial lead for Celgene, joining Celgene as part of the Juno Therapeutics acquisition. At Juno, Mr Kirby built and led commercial functions in his role as vice president of market and market access. Prior to Celgene/Juno, Mr Kirby was the head of marketing at Medivation and spent nearly 15 years in commercial leadership roles at Amgen. In his final role at Amgen, Mr Kirby oversaw the US customer-facing marketing efforts for the G-CSF franchise NEULASTA® and NEUPOGEN®. Mr Kirby’s experience also includes commercial roles at GlaxoSmithKline. Mr Kirby holds an undergraduate degree from the University of Maryland at College Park.

Eckhard S.D. Leifke, MD

Chief Medical Officer

Eckhard S.D. Leifke, MD, joined Omeros as our vice president, clinical development in June 2018 and assumed the role as our chief medical officer in August 2018. He brings to Omeros more than 20 years of drug development experience, having built and headed global teams at leading pharmaceutical companies that include Bayer, Takeda and, most recently, Sanofi, where he was global project head/vice president of early project & external opportunities—cardiovascular and metabolism and global head/vice president of late-stage development diabetes. Dr Leifke has led the global development of multiple early- and late-stage small-molecule and biologic drug candidates to successful market authorizations in the US, Europe, Japan, and other countries. Dr Leifke holds a Medical Doctorate from the University of Freiburg, Germany, and is board-certified in internal medicine and endocrinology.

Justin McCue, PhD

Vice President
Chemistry, Manufacturing and Controls

Justin McCue, PhD, joined Omeros as our vice president of chemistry, manufacturing and controls (CMC) in September 2018. Prior to joining Omeros, Dr McCue headed the development of CAR T-cell and T-cell receptor (TCR) therapy manufacturing processes at Juno Therapeutics (now Celgene). Prior to Celgene, Dr McCue was at Biogen from 2004 to 2017, where he held various positions of increasing responsibility within CMC, including director of manufacturing science, director of product quality management, and leading Biogen’s CMC activities for the multibillion-dollar drugs AVONEX® and PLEGRIDY®. He began his career in the biopharmaceutical division at Millipore. Dr McCue earned his PhD in chemical engineering at Massachusetts Institute of Technology (MIT) after receiving a degree in chemical engineering from the University of California at Berkeley.

Catherine A. Melfi, PhD

Chief Regulatory Officer

Catherine A. Melfi, PhD, joined Omeros as our vice president, regulatory affairs and quality systems in October 2012 and has served as our chief regulatory officer since April 2016. Dr Melfi previously served from 1996 to 2012 at Eli Lilly and Company, where she held technical and leadership roles of increasing scope and responsibility, including as senior director and scientific director in global health outcomes and regulatory affairs, respectively. Prior to joining Lilly, Dr Melfi held various faculty and staff positions at Indiana University, including appointments in its Economics Department, School of Public and Environmental Affairs, and School of Medicine. Dr Melfi received her PhD in economics from the University of North Carolina – Chapel Hill and BS in Economics from John Carroll University.

J. Steven Whitaker MD, JD

Vice President
Clinical Development

J. Steven Whitaker, MD, JD, has served as our vice president, clinical development since joining Omeros in March 2010 and served as our chief medical officer from March 2010 through August 2018. From May 2008 to March 2010, Dr Whitaker served as the chief medical officer, vice president of clinical development at Allon Therapeutics, Inc., a biotechnology company focused on developing drugs for neurodegenerative diseases. From August 2007 to May 2008, he served as a medical consultant to Accelerator Corporation, a biotechnology investment and development company. From May 1994 to May 2007, Dr Whitaker served at ICOS Corporation, which was acquired by Eli Lilly & Company in 2007. At ICOS, he held roles of increasing responsibility in clinical research and medical affairs, most recently as divisional vice president, clinical research as well as medical director of the CIALIS® global product team. Dr Whitaker received his MD from the Indiana University School of Medicine, his JD from the University of Washington, and his BS from Butler University.

Board of Directors

Gregory A. Demopulos, MD

Chairman and Chief Executive Officer

Gregory A. Demopulos, MD, founded our company and has served as our president, chief executive officer, and chairman of the board of directors since June 1994. Prior to founding Omeros, Dr Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training in hand and microvascular surgery at Duke University. Dr Demopulos currently serves on the board of trustees of the Smead Funds Trust, an open-end mutual fund company registered under the Investment Company Act of 1940. Dr Demopulos received his MD from the Stanford University School of Medicine and his BS from Stanford University.

Ray Aspiri

Director

Ray Aspiri has served on our board of directors since January 1995. From his founding of the company in 1997 until its sale in December 2012, Mr Aspiri served as the chairman of the board of Tempress Technologies, Inc., a privately held research and development company that specialized in high-pressure fluid dynamics for the oil and gas industry. From 1980 to 1997, he served as the chairman of the board and chief executive officer of Tempress, Inc., a privately held company specializing in products for the truck, marine, and sporting goods industries.

Thomas F. Bumol, PhD

Director

Dr Bumol is executive director of the recently established Allen Institute for Immunology and a former longtime senior executive at Eli Lilly and Company. Prior to joining the Allen Institute, Dr Bumol was the senior vice president of biotechnology and immunology research and the site head of Lilly’s Biotechnology Center in San Diego. While at Lilly, Dr Bumol’s teams and collaborators advanced over 100 molecules into clinical development, including TRULICITY® (dulaglutide), TALTZ® (ixekizumab), EMGALITY® (galcanezumab), and mirikizumab. Through strategic alliances, he and his teams also helped develop and support REOPRO® (abciximab) with Centocor as well as OLUMIANT® (baricitinib) with Incyte. Dr Bumol has over 50 publications and reviews and 8 issued US patents. Dr Bumol serves on the University of Michigan Technology Transfer National Advisory Board, on the board of directors of Pantheryx, and as an advisor to Lilly Ventures. Dr Bumol earned his BS degree in microbiology from the University of Michigan and his PhD in microbiology-immunology from the University of Minnesota. He completed postdoctoral studies through a fellowship in the Department of Molecular Immunology at Scripps Research in La Jolla, California.

Thomas J. Cable

Lead Independent Director

Thomas J. Cable has served on our board of directors since January 1995. Mr Cable is the vice chairman of the board of the Washington Research Foundation, a technology transfer and early-stage venture capital organization affiliated with the University of Washington, which he cofounded in 1980. He also founded Cable & Howse Ventures, a venture capital firm, and Cable, Howse & Ragen, an investment banking firm, and co-founded Montgomery Securities, an investment banking firm acquired by Bank of America. A former US Navy submarine officer, Mr Cable received his MBA from the Stanford Graduate School of Business and his BA from Harvard University.

Peter A. Demopulos, MD

Director
Peter A. Demopulos, MD, FACC, FSCAI, has served on our board of directors since January 1995. Dr Demopulos is a practicing board-certified general and interventional cardiologist at Seattle Cardiology, part of the Swedish Heart & Vascular Institute. He has been a member of Seattle Cardiology since 2005 and served as its medical director from 2005 to 2010. Dr Demopulos is also a clinical assistant professor of cardiology at the University of Washington School of Medicine, a position that he has held since 1989. He participates as an investigator in clinical trials evaluating interventional cardiology devices and drug therapies at Seattle Cardiovascular Research and Swedish Cardiovascular Research. Dr Demopulos received his MD from the Stanford University School of Medicine and his BS from Stanford University.

Arnold C. Hanish

Director

Arnold C. Hanish has served on our board of directors since September 2012. From 1994 until his retirement in December 2012, Mr Hanish served as vice president and chief accounting officer at Eli Lilly and Company. Prior to his appointment as chief accounting officer, Mr Hanish held a number of senior financial positions at Eli Lilly (currently Lilly). Before Eli Lilly, he held various positions at Arthur Young & Company (currently Ernst & Young) for nearly 14 years. He currently is a member of the Deloitte and Touche Audit Quality Review Council. Mr Hanish was a member of the Standing Advisory Group of the Public Company Accounting Oversight Board from 2004 through 2008 and from 2011 through 2012. In addition, he served from 2007 to 2010 as the chairperson of Financial Executives International’s Committee on Corporate Reporting. Mr Hanish earned his BA in accounting from the University of Cincinnati.

Leroy E. Hood, MD, PhD

Director

Leroy E. Hood, MD, PhD, has served on our board of directors since March 2001. He also has served on our nominating and governance committee since September 2009 and on our compensation committee since July 2011. Dr Hood previously served as a member of our audit committee from September 2009 to December 2009 and from June 2012 to September 2012. Dr Hood has served as senior vice president and chief science officer of Providence Health & Services, a multistate, not-for-profit health system, since April 2016 and is the chief strategy officer of the Institute for Systems Biology, a nonprofit research institute dedicated to the study and application of systems biology. Dr Hood co-founded the Institute for Systems Biology in 2000 and served as its president through December 2017. Previously, Dr Hood was founder and chairman of the Department of Molecular Biotechnology at the University of Washington School of Medicine. Dr Hood also co-founded Amgen, Inc., Applied Biosystems, Inc., Darwin Molecular Technologies, Inc., Rosetta Inpharmatics, Inc., and SyStemix, Inc. Dr Hood is a member of the National Academy of Sciences, American Philosophical Society, American Association of Arts and Sciences, Institute of Medicine, and National Academy of Engineering. Dr Hood received his PhD and BS from the California Institute of Technology and his MD from The Johns Hopkins School of Medicine.

Rajiv Shah, MD

Director

Rajiv Shah, MD has served on our board of directors since June 2015. Dr. Shah is currently president of the Rockefeller Foundation. Before joining the Rockefeller Foundation, he was a distinguished fellow at Georgetown University's School of Foreign Service. Dr. Shah previously served as administrator of the United States Agency for International Development, or USAID, from January 2010 to February 2015. Prior to his appointment at USAID, Dr. Shah served as undersecretary and chief scientist at the US Department of Agriculture, during which time he created the National Institute for Food and Agriculture. Prior to working in government, he spent 8 years at the Bill & Melinda Gates Foundation, where he led efforts in global health, agriculture, and financial services. Dr. Shah currently serves on the board of directors of PanTheryx, Inc. Dr. Shah holds a BS from the University of Michigan, an MSc in health economics from the Wharton School of Business at the University of Pennsylvania, and an MD from the University of Pennsylvania School of Medicine.